AbbVie announced a $195 million investment in its North Chicago, Illinois plant to expand domestic active pharmaceutical ingredient (API) production. This initiative is part of the company’s commitment to invest over $10 billion in the U.S. to support innovation and expand critical manufacturing capabilities.

The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines. Construction will begin in fall 2025, with operations expected to start in 2027.

"Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs," said Robert A. Michael, chairman and chief executive officer, AbbVie. "This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients' lives."

AbbVie’s U.S. manufacturing network spans 11 sites and supports more than 6,000 jobs, in addition to thousands at suppliers. The company employs over 11,000 people in Illinois, where it is headquartered.

"AbbVie’s decision to expand its manufacturing footprint in Illinois is a testament to our state's world-class workforce, infrastructure, cutting-edge research institutions, and location that keeps businesses connected to the nation and the world," said Governor JB Pritzker. "As a global leader in pharmaceuticals, AbbVie’s investment in Illinois bolsters our world-class biomanufacturing ecosystem and creates jobs while it innovates next generation medicines."